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ABSTRACT
Objective: We perform a simple cost estimation of ultrasound gui-
dance for the placement of central venous access, considering the US
federal reimbursement for ultrasound guidance of central line place-
ment to the federal reimbursement for treating the complication of
pneumothorax.
Methods: We utilize national statistics on the number of central lines
placed annually to determine the cost savings incurred if all central lines
placed in the United States were placed with ultrasound guidance.
Results: The initial “cost” of placing central lines was found to be
390,780,000 to 651,300,000 dollars per year by the landmark technique,
as compared with 494,820,000 to 824,700,000 dollars per year by ultra-
sound guidance.
Conclusions: The cost of ultrasound guidance was not mitigated by its
reduction in the cost of treating pneumothoraces.
Keywords: cardiovascular disease prevention, clinical research, cost
analysis, cost savings.
Introduction
We set out to perform a simple study evaluating a partial cost-
effectiveness measure of ultrasound guidance for the placement
of central venous access. Because of the nature of the data,
our analysis is a cost estimation and interpolation study, rather
than a cost-effectiveness analysis [1,2]. The current standard of
practice is changing from the landmark-guided technique to
ultrasound-guided placement in many academic centers. Mul-
tiple meta-analyses have consistently shown a reduction in com-
plication rates using ultrasound-guided central venous access,
coupled with a faster time-to-line placement [3–6]. Ultrasound-
guided placement would appear to be a safer and more efﬁcient
method. The cost-effectiveness of this practice was studied and
reported by the National Institute for Clinical Excellence (NICE)
in the UK in 2002 [6]. Their meta-analysis suggested a 2000-
pound sterling savings for every 1000 central lines placed. Based
on their estimate of 200,000 central lines being placed in the
UK each year, this represents a 400,000 pound/year savings
(748,646.00 US$) (all exchange rates calculated as at June 1,
2006, with 1 USD = 1.8683379534 GBP). Our study differs from
the NICE study by focusing on one complication, pneumotho-
rax, using a cost extrapolation method of analysis, and looking
at the US health-care system.
We utilize national statistics on the number of central lines
placed in the United States annually to determine the theoretical
cost savings incurred if all central lines placed in the United States
were placed with ultrasound guidance. This was done using the
current literature deﬁning the risk reduction associated with
ultrasound-guided central line placement [7], and the resource-
based relative value unit scale (RBRVUS) [3,4].
Methods
Our intent was to perform an economic analysis of ultrasound-
guided central venous access using data from the United States
and the uniquely suited RBRVUS [7,8].
The RBRVUS scale is based on an equation developed over
several years after studying patterns of reimbursement in a
variety of specialities, and in multiple locations. The scale allows
for the quantiﬁcation of physician (professional) and resource
(technical) cost for a given test or procedure. It was then extrapo-
lated to the national level. It is therefore well suited to reﬂect the
potential cost of a procedure to the Nation’s health-care systems.
The cost of a given procedure is represented in relative value
units (RVUs), X. According to the scale, one RVU is equivalent to
a set dollar amount, 37.89$ in 2006, which is adjusted annually
and modiﬁed according to geographic variations in practice and
malpractice expense.
The RVU for a given test or procedure can be broken down
into professional and technical components. Once the RVUs are
determined, the value is multiplied by a conversion factor (CF),
which converts the RVUs to a dollar amount. This conversion
factor is adjusted annually. Each of the estimates was then
obtained by applying the following formula:
Medicare fee Work RVU Work RVU GPCI 
adjustment Facility
= ×[(
] +  PE RVU PE
RVU GPCI adjustment MP RVU
MP RVU GPCI adjus
×[
] + ×[
tment CF]) ×
Where: GPCI = geographical practice index, PE = practice
expense and MP = malpractice.
Geographical variations in cost are accounted for by the use
of a “geographical price index,” which has been determined for
each region. Medicare utilizes this measure nationally; therefore,
we make the assumption that this unit of “cost” can be applied
to national statistics for our theoretical estimates as well.
As a government tool, it is also likely that the “costs” estimated
with this measure will err toward a conservative measurement. We
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accept that the listed cost and actual reimbursement are often not
the same, and therefore this is purely a theoretical analysis.
There are approximately three to 5 million central lines
placed in the United States each year. For these central line
placements, the reimbursement structure is as follows [9,10]:
when a patient has access to some form of insurance, the hospital
bills an insurer. In the case of Medicare, the reimbursement
process combines. We consider the “cost” in RVUs of performing
these lines by the standard landmark and ultrasound-guided
techniques. We begin by looking at the deﬁnable costs associated
with pneumothorax and the treatment of the condition.
Pneumothorax is reported to occur in 1.3% to 1.5% of
landmark-guided central line placements [11–13]. It is not the
only complication, however. Other complications include arterial
punctures, multiple arterial punctures, CPR and intubations [6,7].
The “cost” of a pneumothorax was estimated as the cost of two
and a half additional chest x-rays, as well as the cost of placing a
thoracostomy tube in 20% of patients [14].
We use a median geographical cost index, which in 2006 was
that of the state of Arizona (geographical cost index code—
83200) (See http://www.cms.hhs.gov/apps/pfslookup/ for details
of the codes employed). The cost of a two-view radiograph of the
chest (Current Procedural Technology (CPT) code––71020) was
then estimated at 90.75$ (2.5 ¥ 36.30$/chest x-ray). The cost of a
thoracostomy tube (CPT code––32020) in 20% of patients was
43.74$ (20% of 218.63$/tube), using the same locality.
Although many other costs are incurred with every pneu-
mothorax, our intent was to make a conservative estimate,
assuming that a reduction in complications would translate
directly into a reduction in cost. This total “cost of a pneumotho-
rax” is 134.49$ that is less than the number utilized by the
National Institute for Clinical Excellence. The Boland study [15]
estimated a cost per pneumothorax of 316.02 pounds (598.19$)
but their study included the cost of an overnight stay as well as
the above.
According to the average Medicare reimbursement, as deter-
mined by the RVU scale and the same geographical cost index,
the “cost” of placing a non-tunneled central venous catheter is
130.26$ (CPT code––36556). This is true with either technique.
Nevertheless, the use of ultrasound in a fee for service health-care
system also incurs a cost.
The CPT code used for ultrasound-guided central venous
access by Emergency Physicians before 2004 was 76942. This
code, deﬁned as being appropriate for “echo guide for biopsy” or
“ultrasound guidance for needle placement,” is the code still
utilized for paracentesis, thoracentesis and echo guidance of
abscess drainage. The RVU assigned to this code for 2006 is 3.84
RVUs or 144.84$, given the same assumptions as above. In 2005,
a new code speciﬁc to ultrasound guidance of central venous
access was generated. This code, 76937, yields a markedly dif-
ferent RVU and dollar amount, 91$ and 34.86$, respectively. A
summary of the technical and professional components of these
RVUs is presented in Table 1 below.
Derivation of Ultrasound-Guided versus
Landmark-Guided Central Line Costs
The derivation for the cost of ultrasound-guided versus landmark-
guided central lines using values from 2006 is outlined below:
Landmark technique million lines year:
. , ,
3 5
130 26 390 780 00
− ×
=$ 0 651 300 000− , , $ year
Ultrasound-guided technique million lines year:
.
3 5
130 26 34
− ×
+ . , , , , .68 494 820 000 824 700 000( ) = −
Results
A complication rate of 1.5% yields an annual pneumothorax rate
affecting 39,000 to 75,000 patients in the United States each year.
Using the value of 134.49 dollars derived above, we determined
the theoretical “cost of pneumothorax” in the landmark
technique to be 5,245,110 to 10,086,750 per year (134.49$ ¥
39000–134.49$ ¥ 75000).
This is assuming that all of the lines placed in the United
States are placed with landmark guidance.
Thus we obtain
39 000 134 49 5 245 110, . , ,× =$ $
75 000 134 49 10 086 750, . , ,× =$ $
Several meta-analyses of ultrasound-guided central line place-
ment have suggested a maximal risk reduction of 50% [5,6]. Our
paper avers that there is roughly a 2 to 5 million US dollar annual
savings as a direct result of performing central lines with ultra-
sound guidance.
The initial “cost” of placing central lines was found to be
390,780,000 to 651,300,000 dollars per pear by the landmark
technique as compared with 494,820,000 to 824,700,000 dollars
per year by ultrasound guidance. This is a result of the additional
“cost” of using ultrasound. After subtracting the money saved in
the reduction of the rate of pneumothorax, this billable “cost” of
using ultrasound for central venous access is potentially 104
to 173 million dollars per year above that of performing the
standard landmark technique.
Extra cost of ultrasound guidance—the money saved in reduc-
tion of pneumothoraces: (104–173 million) - 5 million/year =
99–168 million dollars/year.
Given that the complication rate of a paracentesis is similar if
not less than that of central line placement, the time required for
each procedure is roughly equivalent, and the procedure utilized
for sterile preparation, and ultrasound guidance of needle place-
ment, is almost identical for both procedures, it is puzzling that
the relative value of ultrasound guidance for central lines is only
a fourth of that for paracentesis [1]. Using the CPT code from
2004 that previously used for ultrasound-guided central venous
access and still used for other ultrasound-guided procedures, the
cost of placing all of these lines under ultrasound guidance
increases up to 1.37 billion dollars. The cost per pneumothorax
would then need to increase to roughly 14,800$ per pneumotho-
rax to offset the additional cost of ultrasound.
Discussion
We performed a simple cost estimation of ultrasound guidance
for the placement of central venous access, considering the US
federal reimbursement for ultrasound guidance of central line
Table 1 Technical and professional components of the RVU scale
Subject
Technical
Total
RVU
Cost in 2006,
conversion
factor 37.89,
US Dollars ($)
Technical
TC RVU
Professional
TC RVU
Central access (76937) 0.43* 0.48 0.91 34.86
Echo/biopsy (76942) 0.92 2.92 3.84 144.94
*CPT codes, RVUs, the 2006 RVU conversion factor and geographical price indexes were
obtained from the CMS Web site, http://www.cms.hhs.gov/apps/pfslookup.
CPT, Current Procedural Technology; RVU, relative value unit; TC, Technical
Component.
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placement to the federal reimbursement for treating the com-
plication of pneumothorax. We utilized national statistics on
the number of central lines placed annually to determine the
cost savings incurred if all central lines placed in the United
States were placed with ultrasound guidance. We found the
initial “cost” of placing central lines was 390,780,000 to
651,300,000 US dollars per year, by the landmark technique, as
compared with 494,820,000 to 824,700,000 US dollars per
year by ultrasound guidance. The cost of ultrasound guidance
was therefore not mitigated by its reduction in the cost of treat-
ing pneumothoraces.
Our analysis is not a full cost-effectiveness analysis because
cost, although related, is not the same as reimbursement or
charge for service [1,2,16,17]. This is therefore a partial cost-
effectiveness analysis of ultrasound-guided central line place-
ment versus the landmark technique offsetting the Centers for
Medicare Services (CMS) reimbursement for ultrasound guid-
ance against the CMS reimbursement for one complication––
pnuemothorax. Pneumothorax is not the only complication
forthcoming from these procedures, and so our estimates are
necessarily incomplete. Other complications include arterial
punctures, multiple arterial punctures, cardiopulmonary resus-
citation (CPR) and intubation [6,7]. For example, the National
Institute for Clinical Excellence also assigned a 40 pound ster-
ling ($78) cost to arterial puncture [6], which is also a
common, data on which would change the ﬁndings slightly.
One heroic assumption we make is to assume a linear causal
path between reductions in pnuemothoraces and cost reduc-
tions overall.
This analysis was designed to evaluate the economic beneﬁt
of ultrasound-guided central lines in terms of risk reduction of
pneumothorax. We did this only partially and conservatively in
light of the 99- to 168-million-dollar difference in techniques that
was found in stark contrast to the ﬁndings of the UK’s National
Institute for Clinical Excellence analysis. It is obvious that many
elements of morbidity associated with a procedure are difﬁcult to
quantify, and the beneﬁt of using ultrasound guidance for central
line placement argues for this practice. The intention of the
authors is to highlight the perspective offered by this analysis in
light of the economic issues faced by our collective health-care
environment.
As a theoretical analysis, it is difﬁcult to conclude with
speciﬁc recommendations regarding changes in clinical practice.
Ultrasound-guided central line placement does appear to
improve patient care, but may, on a national level, come at a high
cost. The change in RVUs assigned to central line placement from
2004 to 2005 should prompt investigation into how far the
resource-based RVU scale has drifted from its origin and if this
term is still a fair description of the scale Medicare uses today.
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